作者
Lior Katz, Javier P Gisbert, Beth Manoogian, Kirk Lin, Casper Steenholdt, Gerassimos J Mantzaris, Ashish Atreja, Yulia Ron, Arun Swaminath, Somal Shah, Ailsa Hart, Peter Laszlo Lakatos, Pierre Ellul, Eran Israeli, Mads Naundrup Svendsen, C Janneke Van Der Woude, Konstantinos H Katsanos, Laura Yun, Epameinondas V Tsianos, Torben Nathan, Maria Abreu, Iris Dotan, Bret Lashner, Jorn Brynskov′, Jonathan P Terdiman, Peter DR Higgins, Maria Chaparro, Shomron Ben‐Horin
发表日期
2012/11
期刊
Inflammatory bowel diseases
卷号
18
期号
11
页码范围
2026-2033
出版商
Wiley Subscription Services, Inc., A Wiley Company
简介
Background
Intensifying infliximab therapy is often practiced in Crohn's disease (CD) patients losing response to the drug but there are no data if halving the interval is superior to doubling the dose. We aimed to assess the efficacy of infliximab dose intensification by interval‐halving compared with dose‐doubling.
Methods
A multicenter retrospective study of CD patients losing response to infliximab was undertaken. The clinical outcome of patients whose infusion intervals were halved (5 mg/kg/4 weeks) was compared with patients treated by dose‐doubling (10 mg/kg/8 weeks).
Results
In all, 168 patients were included from 18 centers in Europe, USA, and Israel. Of these, 112 were intensified by dose‐doubling and 56 received interval‐halving strategy. Early response to dose‐escalation was experienced by 86/112 (77%) patients in the dose‐doubling group compared with 37/56 patients (66%) in the interval …
学术搜索中的文章
L Katz, JP Gisbert, B Manoogian, K Lin, C Steenholdt… - Inflammatory bowel diseases, 2012